在囊性纤维化中绘制氧化景观:方法边界和应用
Michela Rubin1, Ilaria Artusi1,2, Giorgio Cozza1,3
1Department of Molecular Medicine (DMM), University of Padua, Padua, Italy.
Frontiers in pharmacology
|July 31, 2025
概括
囊性纤维化 (CF) 研究需要更好的方法来测量氧化应激. 本综述分析了检测氧化应激标志物的方法,这对于开发针对CF患者的向抗氧化疗法至关重要.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 医学研究 医学研究
背景情况:
- 囊性纤维化 (CF) 是一种由CFTR基因突变驱动的多器官疾病.
- 肌痛性肺炎的特征是渐进的肺病,慢性炎症和增加的氧化应激.
- 了解CFTR功能障碍,氧化应激和炎症之间的联系是治疗开发的关键.
研究的目的:
- 审查和分析用于鉴定囊性纤维化中氧化应激标志物的方法.
- 突出应用,结果和当前方法中的潜在不一致性.
- 倡导综合策略来评估CF中的氧化还原失调.
主要方法:
- 对检测活性氧物种 (ROS) 的分析技术的审查.
- 分析评估脂质,蛋白质和DNA氧化损伤的方法.
- 包括抗氧化剂,抗氧化剂系统和线粒体功能的测试.
- 讨论实验模型和生物样本的考虑.
主要成果:
- 高度氧化应激和改变的抗氧化防御在CF中经常在各种生物体内观察到.
- 方法包括直接检测ROS,氧化损伤评估 (脂质,蛋白质,DNA),抗氧化剂测定和线粒体功能.
- 实验变化和模型/样本的选择可以影响结果.
结论:
- 在CF中评估氧化应激是复杂的,需要采用多参数方法.
- 结合互补方法的综合策略对于全面了解氧化还原失衡至关重要.
- 可靠的生物标志物和向的抗氧化疗法可以通过全面的氧化还原评估来确定.
更多相关视频
09:33Imaging Approaches to Assessments of Toxicological Oxidative Stress Using Genetically-encoded Fluorogenic Sensors
Published on: February 7, 2018
7.5K
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.4K
相关概念视频
Cystic Fibrosis: Pathogenesis
366
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
366
Cystic Fibrosis: Management
224
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
224
